Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of reduced tocilizumab dosing frequency in sJIA patients with laboratory abnormalities
2012-000444-10Phase 4Completed
- Sponsor
- Roche
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in systemic juvenile idiopathic arthritis (SJIA) and juvenile idiopathic arthritis (JIA), sponsored by Roche. Primary endpoint: Efficacy. Started Aug 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2012-000444-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000444-10.